{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:35:47Z","timestamp":1784666147498,"version":"3.55.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Egyptian Bureau for Cultural & Educational Affairs in London"},{"name":"The Birmingham Lupus Cohort"},{"DOI":"10.13039\/501100018817","name":"Lupus UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018817","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Cutaneous vasculitis (CV) is common in SLE, but the epidemiology and risk factors remain unclear. We aimed to identify the trends and risk factors for CV in patients with SLE over a period of 20\u2009years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Birmingham Lupus Cohort is an observational longitudinal cohort of SLE patients. Patients were enrolled within 3\u2009years of meeting their fourth ACR criterion. Disease activity, laboratory test results and treatment records were collected. A multivariable shared frailty Cox proportional hazard model was used to identify clinical, laboratory and treatment-related variables associated with the development of CV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 392 patients: 95.7% were female. The median (interquartile range) duration of follow-up was 9.2 (5.1\u201314.7) years. CV occurred in 27% of SLE patients, of whom 43.3% had two or more CV events. This study demonstrated a marked decline in the incidence rates of CV, decreasing from 34.4% (95% CI 29.7, 39.3) during the first 3\u2009years after enrolment to 2.1% (95% CI 0.05, 11.5) after 18\u2009years of follow-up. Development of CV was associated with RP, constitutional, mucocutaneous, musculoskeletal, haematological and cardiovascular involvement, anti-Sm antibodies, anti-dsDNA, and hypocomplementemia. However, the use of AZA and antimalarials was inversely associated with the development of CV. Patients with CV were more likely to develop at least one item of organ damage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The incidence rates of CV in SLE decreased over the follow-up period and CV is associated with defined clinical, serological and treatment-related factors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae672","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:14:12Z","timestamp":1733955252000},"page":"2749-2755","source":"Crossref","is-referenced-by-count":3,"title":["Cutaneous vasculitis in systemic lupus erythematosus: epidemiology and risk factors over a 20-year follow-up"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6814-8704","authenticated-orcid":false,"given":"Ahmed","family":"Saleh","sequence":"first","affiliation":[{"name":"Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham , Birmingham,","place":["UK"]},{"name":"Rheumatology Department, Faculty of Medicine, Mansoura University , Mansoura,","place":["Arab Republic of Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1715-4869","authenticated-orcid":false,"given":"Chee-Seng","family":"Yee","sequence":"additional","affiliation":[{"name":"Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust , Doncaster,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aba","family":"Acquah","sequence":"additional","affiliation":[{"name":"Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1244-6443","authenticated-orcid":false,"given":"Caroline","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham , Birmingham,","place":["UK"]},{"name":"Rheumatology Department, Sandwell and West Birmingham NHS Trust , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-4404","authenticated-orcid":false,"given":"John A","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham , Birmingham,","place":["UK"]},{"name":"Rheumatology Department, Sandwell and West Birmingham NHS Trust , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"2025050316141120600_keae672-B1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/0975-7406.135247","article-title":"Anti-nuclear antibodies positive serum from systemic lupus erythematosus patients promotes cardiovascular manifestations and the presence of human antibody in the brain","volume":"6","author":"Kelly-Worden","year":"2014","journal-title":"J Pharm Bioallied Sci"},{"key":"2025050316141120600_keae672-B2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025050316141120600_keae672-B3","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1177\/0961203313502571","article-title":"Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes","volume":"22","author":"Gonz\u00e1lez","year":"2013","journal-title":"Lupus"},{"key":"2025050316141120600_keae672-B4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316141120600_keae672-B5","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.3390\/biomedicines9111626","article-title":"Lupus vasculitis: an overview","volume":"9","author":"Leone","year":"2021","journal-title":"Biomedicines"},{"key":"2025050316141120600_keae672-B6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11926-006-0015-5","article-title":"Vasculitis associated with connective tissue disorders","volume":"8","author":"Doyle","year":"2006","journal-title":"Curr Rheumatol Rep"},{"key":"2025050316141120600_keae672-B7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/096120339700600304","article-title":"Vasculitis in systemic lupus erythematosus","volume":"6","author":"Drenkard","year":"1997","journal-title":"Lupus"},{"key":"2025050316141120600_keae672-B8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/01.md.0000216817.35937.70","article-title":"Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients","volume":"85","author":"Ramos-Casals","year":"2006","journal-title":"Medicine (Baltimore)"},{"key":"2025050316141120600_keae672-B9","first-page":"447","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay","year":"1993","journal-title":"Q J Med"},{"key":"2025050316141120600_keae672-B10","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000411","article-title":"Cutaneous vasculitis in SLE","volume":"7","author":"Kallas","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2025050316141120600_keae672-B11","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/0961203317739134","article-title":"Cutaneous vasculitis in systemic lupus erythematosus patients: potential key players and implications","volume":"27","author":"Gheita","year":"2018","journal-title":"Lupus"},{"key":"2025050316141120600_keae672-B12","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025050316141120600_keae672-B13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1191\/096120300672904669","article-title":"From BILAG to BLIPS\u2014disease activity assessment in lupus past, present and future","volume":"9","author":"Isenberg","year":"2000","journal-title":"Lupus"},{"key":"2025050316141120600_keae672-B14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2025050316141120600_keae672-B15","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/rheumatology\/keu412","article-title":"Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years","volume":"54","author":"Yee","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316141120600_keae672-B16","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/sj.bjc.6602102","article-title":"A note on competing risks in survival data analysis","volume":"91","author":"Satagopan","year":"2004","journal-title":"Br J Cancer"},{"key":"2025050316141120600_keae672-B17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-statistics-032921-021310","article-title":"Shared frailty methods for complex survival data: a review of recent advances","volume":"10","author":"Gorfine","year":"2023","journal-title":"Annu Rev Stat Appl"},{"key":"2025050316141120600_keae672-B18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/insr.12214","article-title":"A tutorial on multilevel survival analysis: methods, models and applications","volume":"85","author":"Austin","year":"2017","journal-title":"Int Stat Rev"},{"key":"2025050316141120600_keae672-B19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/1536867X1501500109","article-title":"Frailty models and frailty-mixture models for recurrent event times","volume":"15","author":"Xu","year":"2015","journal-title":"Stata J"},{"key":"2025050316141120600_keae672-B20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2288-10-20","article-title":"Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer","volume":"10","author":"Bellera","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"2025050316141120600_keae672-B21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/ard-2023-224919","article-title":"Pragmatic targets for moderate\/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression","volume":"83","author":"Pitsigavdaki","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025050316141120600_keae672-B22","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1177\/0961203309106177","article-title":"Digital vasculitis in systemic lupus erythematosus: a minor manifestation of disease activity?","volume":"18","author":"Gomes","year":"2009","journal-title":"Lupus"},{"key":"2025050316141120600_keae672-B23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/acr.21581","article-title":"Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort","volume":"64","author":"Santiago-Casas","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025050316141120600_keae672-B24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.rbr.2017.05.008","article-title":"Initial digital vasculitis in a large multicenter cohort of childhood-onset systemic lupus erythematosus","volume":"57","author":"Sakamoto","year":"2017","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"2025050316141120600_keae672-B25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10067-008-1043-5","article-title":"Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus","volume":"28","author":"Fukuda","year":"2009","journal-title":"Clin Rheumatol"},{"key":"2025050316141120600_keae672-B26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/0961203316645204","article-title":"A study of the influence of ethnicity on serology and clinical features in lupus","volume":"26","author":"Morais","year":"2017","journal-title":"Lupus"},{"key":"2025050316141120600_keae672-B27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0889-857X(05)70143-5","article-title":"Update on cyclophosphamide for systemic lupus erythematosus","volume":"26","author":"Ortmann","year":"2000","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae672\/61051495\/keae672.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2749\/61051495\/keae672.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2749\/61051495\/keae672.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:14:26Z","timestamp":1746303266000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/5\/2749\/7921424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,11]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae672","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,11]]}}}